Ergotamine and triptans induced medication-overuse headache: a real-world population-based comparative study from the Northern Thai headache registry
Ergotamine-induced MOH is linked to more severe withdrawal symptoms, whereas dual-MOH carries the greatest risk of recurrence. These findings highlight the importance of tailored withdrawal strategies and close monitoring, particularly in resource-limited settings where ergotamine remains widely available. They also support policy initiatives aimed at restricting over-the-counter ergotamine and expanding access to safer acute treatment options.
Authors
- Chutithep Teekaput (ORCID: https://orcid.org/0000-0002-3019-1210)
- Kitti Thiankhaw (ORCID: https://orcid.org/0000-0002-0556-541X)
- Surat Tanprawate
- Kanokkarn Teekaput
- Watthikorn Chusilthong
- Vipanee Muangchean
- Sirinada Ma-imjai
- Noratham Chalapati
Institutions
- Maharaj Nakorn Chiang Mai Hospital (TH)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Chiang Mai University (TH)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1186/s10194-025-02161-6
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chiang Mai University
- Faculty of Medicine, Chiang Mai University